Article

A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation

2020-05-16

Abstract excerpt

BCR-Abl is a driver oncogene that causes chronic myeloid leukemia and a subset of acute lymphoid leukemias. Although tyrosine kinase inhibitors provide an effective treatment for these diseases, they generally do not kill leukemic stem cells. Leukemic stem cells are cancer-initiating cells that compete with normal hematopoietic stem cells for the bone marrow niche. Using BCR-Abl as a model oncogene, we performed a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2f8ef0ba-3a3f-582a-832f-15083eb4f1f6
DOI: 10.1101/2020.05.16.089755

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activationDOI 10.1101/2020.05.16.089755Read

Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletionSemantic proximity Read

Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrestSemantic proximity Read

A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin ribosideSemantic proximity Read

Cell-based methods for the identification of MYC-inhibitory small molecules.Semantic proximity Read

Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cellsSemantic proximity Read

Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cellsSemantic proximity Read

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.Semantic proximity Read

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic AgentsSemantic proximity Read

Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity LibrarySemantic proximity Read

Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cellsSemantic proximity Read

Quinoline-5,8-Dione CDC25 Inhibitors: Potent Anti-Cancer Agents in Leukemia and Patient-Derived Colorectal OrganoidsSemantic proximity Read

Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.Semantic proximity Read